Revolution Medicines, Inc.

Revolution Medicines ended Q2 2026 with $3.9 billion in cash and investments, including $2.2 billion of gross proceeds from April equity and convertible note offerings and a second $250 million royalty tranche from Royalty Pharma, with up to an additional $1.5 billion in committed flexible capital available subject to milestones. Q2 2026 R&D expense was $395 million versus $224 million a year ago, G&A was $110 million versus $41 million, and net loss was $644 million versus $248 million. Net loss included a $151 million noncash charge tied to the change in fair value of assumed EQRx warrants. Full-year 2026 GAAP operating expense guidance was raised to $2.1 billion-$2.2 billion, including $270 million-$290 million of stock-based compensation, driven by higher manufacturing, clinical development, and commercial readiness spending.

Mark Goldsmith framed 2026 as a transformational year and repeatedly emphasized urgency, breadth, and optionality across the pipeline. He highlighted the RASolute 302 pancreatic data as paradigm-changing, said the company is moving quickly toward access and launch readiness, and stressed that Revolution Medicines is building multiple paths across pancreatic cancer, lung cancer, and potentially colorectal cancer. His tone was confident and expansive, but he also emphasized responsibility and the need to develop several treatment options rather than commit early to a single strategy.

Jack Anders said the balance sheet remains “exceptionally strong,” with $3.9 billion in cash and investments at quarter-end, supported by April financing proceeds and the Royalty Pharma tranche. He cited the sharp year-over-year increases in spending: R&D rose to $395 million from $224 million, G&A to $110 million from $41 million, and net loss to $644 million from $248 million, with higher clinical, manufacturing, headcount, and commercialization costs driving the increase. He also updated 2026 GAAP operating expense guidance to $2.1 billion-$2.2 billion and said the company expects $270 million-$290 million of stock-based compensation.

Analysts pressed on colorectal cancer proof-of-concept, whether daraxonrasib or other RAS approaches can compete in first-line lung cancer, crossover risk in frontline PDAC trials, and how the company plans to position multi-selective versus mutant-selective assets. Management largely declined to give detailed CRC timing or registry-path commitments, saying more concrete guidance would come with data later in the year. On lung cancer, management said elironrasib looks highly competitive and that the portfolio is designed to address over 70% of RAS-mutant NSCLC; on PDAC crossover, they said they are managing geography and patient education carefully to protect trial integrity. They also said the EAP approval/rejection process is mostly eligibility-driven, with seamless transition to commercial supply expected after approval.